- Director, Value Creation, Private Investments
Skip to main content
- Funds
- Insights
- Capabilities
- About Us
- My Account
United States, Intermediary
Changechevron_rightThank you for your registration
You will shortly receive an email with your unique link to our preference center.
The views expressed are those of the authors at the time of writing. Other teams may hold different views and make different investment decisions. The value of your investment may become worth more or less than at the time of original investment. While any third-party data used is considered reliable, its accuracy is not guaranteed. For professional, institutional, or accredited investors only.
At Wellington’s Venture Summit, an intersection of public- and private-market experts dove into key topics for private companies navigating their next stage of growth.
One major takeaway was how early IPO preparation can help companies better navigate potential pitfalls on the way to the public markets.
Below, we highlight five IPO-preparation lessons learned from our panel of Sam Cox (public-market portfolio manager), Josh Sommerfeld (private-market deal lead), and Drew Morales (the associate director of our Value Creation team). With the IPO market currently on pause, we think these tips can help companies that are months and even years away from a public offering.
Going public is one of the most important moments in the life of a company and it can be just as complicated. In our view, these five lessons are just the tip of the iceberg. Our Value Creation team works alongside our private-market deal teams and public-market experts to help our portfolio companies navigate the challenging (and exciting) path to IPO.
Visit our Value Creation homepage for more information.
Experts
Innovation in late-stage private markets
Continue readingThe intersection of AI and private credit
Continue readingMultiple authors
Early-stage venture: Innovation versus hype
Continue readingPrivate biotech innovation versus hype
Continue readingSizing private-market allocations
Continue readingSeatGeek deal overview
Continue readingPrivate biotech market update: IPOs, M&A, and innovation
Continue readingMultiple authors
URL References
Related Insights
Stay up to date with the latest market insights and our point of view.
Thank you for your registration
You will shortly receive an email with your unique link to our preference center
Innovation in late-stage private markets
Matt Witheiler, head of Late-stage Growth, explores innovation and hype in late-stage private markets, discussing AI and defense technology.
The intersection of AI and private credit
Our private credit experts highlight AI's influence on asset class’s market growth, emphasizing how investments in infrastructure like data centers has the potential to drive long-term market opportunity.
Multiple authors
Early-stage venture: Innovation versus hype
Wellington Access Ventures' Jackson Cummings discusses promising innovations in edge AI and embedded fintech. In addition, he highlights the potential hype surrounding consumer AI and quantum computing.
Private biotech innovation versus hype
Nilesh Kumar discusses the next generation of biotech disruptors in obesity, autoimmunity, and oncology, focusing on drugs that solve real-world unmet medical needs.
Sizing private-market allocations
Our multi-asset experts explore three key components of sizing private market allocations, offering a framework to evaluate the capacity to take on illiquidity, the need for excess return, and the ability to consistently source 'good' investments.
SeatGeek deal overview
Head of Late-stage Growth Matt Witheiler and Equity Research Analyst Peter Blain highlight their insights on Wellington’s investment in SeatGeek, discussing the company's potential in primary and secondary ticketing in the growing ticketing landscape.
Private biotech market update: IPOs, M&A, and innovation
Our biotech venture capital experts explore the state of the private biotech market, highlighting the potential IPO-market rebound, surge in private M&A, and the focus on clinical-stage opportunities.
Multiple authors
Databricks deal overview
Head of Late-stage Growth Matt Witheiler and Global Industry Analyst James McNay discuss their work together on Wellington’s investment in Databricks, highlighting the company’s innovation in AI and data analytics amid the evolving tech landscape.
Private market update
Check out our collection of videos on the state of the venture capital and private credit markets, featuring leaders from across our private investing platform.
Multiple authors
When will capital come back to private equity?
Head of Multi-Asset Strategy Adam Berger and Head of Late-Stage Growth Matt Witheiler consider the state of the private equity market, including liquidity challenges, the effects of higher interest rates, late-stage opportunities, and the impact of AI.
Early-stage venture: Deployment, valuations, exits
Head of Wellington Access Ventures Jackson Cummings discusses his latest views on early-stage venture capital and why he’s “cautiously optimistic” on deployments, valuations, and exits.
URL References
Related Insights
© Copyright 2025 Wellington Management Company LLP. All rights reserved. WELLINGTON MANAGEMENT ® is a registered service mark of Wellington Group Holdings LLP. For institutional or professional investors only.
Enjoying this content?
Get similar insights delivered straight to your inbox. Simply choose what you’re interested in and we’ll bring you our best research and market perspectives.
Thank you for joining our email preference center.
You’ll soon receive an email with a link to access and update your preferences.